nodes	percent_of_prediction	percent_of_DWPC	metapath
Vigabatrin—GABBR1—blood—hematologic cancer	0.0107	0.0891	CbGeAlD
Vigabatrin—GABBR1—bone marrow—hematologic cancer	0.0104	0.0863	CbGeAlD
Vigabatrin—SLC36A1—gonad—hematologic cancer	0.00969	0.0804	CbGeAlD
Vigabatrin—ABAT—gonad—hematologic cancer	0.00963	0.0799	CbGeAlD
Vigabatrin—GABBR1—lung—hematologic cancer	0.00942	0.0781	CbGeAlD
Vigabatrin—GABBR1—testis—hematologic cancer	0.00889	0.0737	CbGeAlD
Vigabatrin—ABAT—blood—hematologic cancer	0.00839	0.0696	CbGeAlD
Vigabatrin—SLC36A1—bone marrow—hematologic cancer	0.00817	0.0678	CbGeAlD
Vigabatrin—SLC36A1—lung—hematologic cancer	0.0074	0.0614	CbGeAlD
Vigabatrin—ABAT—lung—hematologic cancer	0.00736	0.061	CbGeAlD
Vigabatrin—SLC36A1—testis—hematologic cancer	0.00698	0.0579	CbGeAlD
Vigabatrin—L-Glutamine—GMPS—hematologic cancer	0.00698	0.388	CrCbGaD
Vigabatrin—L-Glutamine—TGM6—hematologic cancer	0.00698	0.388	CrCbGaD
Vigabatrin—ABAT—testis—hematologic cancer	0.00694	0.0576	CbGeAlD
Vigabatrin—GABBR1—lymph node—hematologic cancer	0.00644	0.0534	CbGeAlD
Vigabatrin—SLC36A1—lymph node—hematologic cancer	0.00506	0.042	CbGeAlD
Vigabatrin—ABAT—lymph node—hematologic cancer	0.00503	0.0417	CbGeAlD
Vigabatrin—L-Glutamine—ASNS—hematologic cancer	0.00401	0.223	CrCbGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	0.000445	0.0048	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CNR2—hematologic cancer	0.000411	0.00443	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—PRKCG—hematologic cancer	0.000409	0.00441	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—CREB1—hematologic cancer	0.000402	0.00434	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—hematologic cancer	0.000397	0.00429	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	0.00039	0.00421	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RHOJ—hematologic cancer	0.000378	0.00408	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ARHGEF12—hematologic cancer	0.00037	0.00399	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—PRKCG—hematologic cancer	0.000368	0.00397	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ARHGEF1—hematologic cancer	0.000361	0.00389	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	0.000357	0.00385	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000356	0.00384	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CCL3—hematologic cancer	0.000354	0.00381	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000351	0.00379	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—PTHLH—hematologic cancer	0.00035	0.00377	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—PTGER4—hematologic cancer	0.00034	0.00367	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—NUP98—hematologic cancer	0.000337	0.00363	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IFT172—hematologic cancer	0.000337	0.00363	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—ARHGEF12—hematologic cancer	0.000336	0.00362	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—hematologic cancer	0.000333	0.00359	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—ARHGEF1—hematologic cancer	0.000327	0.00353	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	0.000327	0.00353	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—NUP214—hematologic cancer	0.000325	0.0035	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	0.000318	0.00343	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCR5—hematologic cancer	0.000317	0.00342	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—PRKCG—hematologic cancer	0.000313	0.00338	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PPEF1—hematologic cancer	0.000308	0.00332	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GNA13—hematologic cancer	0.000307	0.00331	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—CREB1—hematologic cancer	0.000303	0.00326	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—TIAM1—hematologic cancer	0.000302	0.00325	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CXCR4—hematologic cancer	0.000301	0.00324	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—BRAF—hematologic cancer	0.000299	0.00322	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—MDM2—hematologic cancer	0.000294	0.00318	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CCL17—hematologic cancer	0.000294	0.00317	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—JAK3—hematologic cancer	0.000292	0.00315	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCR5—hematologic cancer	0.000288	0.00311	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—TFRC—hematologic cancer	0.000284	0.00306	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCL13—hematologic cancer	0.00028	0.00302	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CCR7—hematologic cancer	0.00028	0.00302	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GNA13—hematologic cancer	0.000278	0.003	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—TIAM1—hematologic cancer	0.000274	0.00295	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—IL3RA—hematologic cancer	0.000273	0.00295	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—CREB1—hematologic cancer	0.000273	0.00294	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—BRAF—hematologic cancer	0.000269	0.0029	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—JAK3—hematologic cancer	0.000266	0.00286	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—RGS2—hematologic cancer	0.000264	0.00284	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—TRIO—hematologic cancer	0.000261	0.00281	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—TRH—hematologic cancer	0.000261	0.00281	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CCR7—hematologic cancer	0.000255	0.00275	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCL13—hematologic cancer	0.000255	0.00275	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—LPAR1—hematologic cancer	0.000252	0.00272	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—MDM2—hematologic cancer	0.00025	0.0027	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—IL3RA—hematologic cancer	0.000248	0.00268	CbGpPWpGaD
Vigabatrin—SLC36A1—SLC-mediated transmembrane transport—ALB—hematologic cancer	0.000244	0.00264	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HDAC11—hematologic cancer	0.000243	0.00263	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—RGS2—hematologic cancer	0.000239	0.00258	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—CYCS—hematologic cancer	0.000238	0.00257	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—TRIO—hematologic cancer	0.000237	0.00255	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—TRH—hematologic cancer	0.000237	0.00255	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—BCR—hematologic cancer	0.000233	0.00252	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PDE4B—hematologic cancer	0.000232	0.00251	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CNR2—hematologic cancer	0.000232	0.00251	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—CREB1—hematologic cancer	0.000232	0.0025	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—LPAR1—hematologic cancer	0.000229	0.00247	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—BRAF—hematologic cancer	0.000229	0.00247	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—RAC2—hematologic cancer	0.000229	0.00247	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—MDM2—hematologic cancer	0.000226	0.00243	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—ADCY7—hematologic cancer	0.000218	0.00236	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HDAC10—hematologic cancer	0.000217	0.00234	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PDE4B—hematologic cancer	0.000211	0.00228	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CNR2—hematologic cancer	0.000211	0.00228	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—RAC2—hematologic cancer	0.000208	0.00224	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	0.000199	0.00214	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ARHGEF12—hematologic cancer	0.000198	0.00214	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—ADCY7—hematologic cancer	0.000198	0.00214	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PTHLH—hematologic cancer	0.000198	0.00213	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ARHGEF1—hematologic cancer	0.000193	0.00209	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PTGER4—hematologic cancer	0.000192	0.00207	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—MDM2—hematologic cancer	0.000192	0.00207	CbGpPWpGaD
Vigabatrin—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—hematologic cancer	0.000183	0.00197	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CCL3—hematologic cancer	0.000181	0.00196	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PTHLH—hematologic cancer	0.000179	0.00193	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PTGER4—hematologic cancer	0.000175	0.00188	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CCL17—hematologic cancer	0.000173	0.00187	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AGRN—hematologic cancer	0.000173	0.00187	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CXCR5—hematologic cancer	0.00017	0.00184	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CXCR4—hematologic cancer	0.00017	0.00183	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—LEF1—hematologic cancer	0.000167	0.0018	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GNA13—hematologic cancer	0.000164	0.00177	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—IL3—hematologic cancer	0.000164	0.00177	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TIAM1—hematologic cancer	0.000162	0.00175	CbGpPWpGaD
Vigabatrin—ABAT—Transmission across Chemical Synapses—HRAS—hematologic cancer	0.000162	0.00174	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—RASGRP1—hematologic cancer	0.000158	0.00171	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR ligand binding—CCL2—hematologic cancer	0.000158	0.0017	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—JAK3—hematologic cancer	0.000157	0.00169	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CXCR4—hematologic cancer	0.000154	0.00166	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CXCL13—hematologic cancer	0.00015	0.00162	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CCR7—hematologic cancer	0.00015	0.00162	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—IL3—hematologic cancer	0.000149	0.0016	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NCOR2—hematologic cancer	0.000148	0.0016	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IL3RA—hematologic cancer	0.000147	0.00158	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CRKL—hematologic cancer	0.000147	0.00158	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—RASGRP1—hematologic cancer	0.000144	0.00155	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—GRB2—hematologic cancer	0.000142	0.00154	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RGS2—hematologic cancer	0.000141	0.00153	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TRIO—hematologic cancer	0.00014	0.00151	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CMA1—hematologic cancer	0.00014	0.00151	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TRH—hematologic cancer	0.00014	0.00151	CbGpPWpGaD
Vigabatrin—GABBR1—Transmission across Chemical Synapses—HRAS—hematologic cancer	0.000137	0.00148	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AGO2—hematologic cancer	0.000137	0.00148	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SPHK1—hematologic cancer	0.000137	0.00148	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HDAC9—hematologic cancer	0.000135	0.00146	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—LPAR1—hematologic cancer	0.000135	0.00146	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—H3F3B—hematologic cancer	0.000134	0.00145	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	0.000133	0.00143	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—GRB2—hematologic cancer	0.000129	0.0014	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—CSF2—hematologic cancer	0.000127	0.00137	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PDE4B—hematologic cancer	0.000125	0.00134	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CNR2—hematologic cancer	0.000125	0.00134	CbGpPWpGaD
Vigabatrin—SLC36A1—Transmembrane transport of small molecules—ALB—hematologic cancer	0.000124	0.00134	CbGpPWpGaD
Vigabatrin—ABAT—Neuronal System—HRAS—hematologic cancer	0.000124	0.00134	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—FGF19—hematologic cancer	0.000124	0.00133	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PRKCG—hematologic cancer	0.000123	0.00133	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—JAK1—hematologic cancer	0.000123	0.00133	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RAC2—hematologic cancer	0.000123	0.00132	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—DKK1—hematologic cancer	0.000122	0.00131	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—STAT5B—hematologic cancer	0.000121	0.0013	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—ADCY7—hematologic cancer	0.000117	0.00126	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CSF2—hematologic cancer	0.000116	0.00125	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—IL2RA—hematologic cancer	0.000115	0.00124	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—XIAP—hematologic cancer	0.000114	0.00123	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PRKCG—hematologic cancer	0.000112	0.0012	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—JAK1—hematologic cancer	0.000112	0.0012	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SMARCA4—hematologic cancer	0.000111	0.0012	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SH2B3—hematologic cancer	0.000111	0.0012	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—GZMB—hematologic cancer	0.00011	0.00119	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CTNNA1—hematologic cancer	0.000108	0.00116	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—EIF4EBP1—hematologic cancer	0.000107	0.00116	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HSPB1—hematologic cancer	0.000107	0.00116	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CCL3—hematologic cancer	0.000107	0.00116	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PTHLH—hematologic cancer	0.000106	0.00114	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SDC1—hematologic cancer	0.000106	0.00114	CbGpPWpGaD
Vigabatrin—GABBR1—Neuronal System—HRAS—hematologic cancer	0.000105	0.00114	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—IL2RA—hematologic cancer	0.000104	0.00112	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PTGER4—hematologic cancer	0.000103	0.00111	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—LCK—hematologic cancer	0.000103	0.00111	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—H3F3A—hematologic cancer	0.000101	0.00109	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PRKCZ—hematologic cancer	9.78e-05	0.00105	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CG—hematologic cancer	9.56e-05	0.00103	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PARP1—hematologic cancer	9.44e-05	0.00102	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—FBXW7—hematologic cancer	9.29e-05	0.001	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CXCR4—hematologic cancer	9.11e-05	0.000983	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HDAC2—hematologic cancer	9.11e-05	0.000983	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CBL—hematologic cancer	8.88e-05	0.000958	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IL3—hematologic cancer	8.79e-05	0.000948	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CG—hematologic cancer	8.68e-05	0.000936	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PTPN1—hematologic cancer	8.64e-05	0.000932	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PTPN11—hematologic cancer	8.53e-05	0.00092	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—RASGRP1—hematologic cancer	8.5e-05	0.000917	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SYK—hematologic cancer	8.47e-05	0.000914	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HSP90AA1—hematologic cancer	8.47e-05	0.000914	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CD—hematologic cancer	8.4e-05	0.000906	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CREB1—hematologic cancer	8.26e-05	0.000891	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—STAT1—hematologic cancer	8.17e-05	0.000881	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—CCL2—hematologic cancer	8.08e-05	0.000872	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—IL6R—hematologic cancer	8.06e-05	0.000869	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3R1—hematologic cancer	7.93e-05	0.000856	CbGpPWpGaD
Vigabatrin—Hypersensitivity—Etoposide—hematologic cancer	7.82e-05	0.000102	CcSEcCtD
Vigabatrin—Tinnitus—Epirubicin—hematologic cancer	7.8e-05	0.000102	CcSEcCtD
Vigabatrin—Malnutrition—Methotrexate—hematologic cancer	7.79e-05	0.000101	CcSEcCtD
Vigabatrin—Headache—Gemcitabine—hematologic cancer	7.78e-05	0.000101	CcSEcCtD
Vigabatrin—Nausea—Vincristine—hematologic cancer	7.78e-05	0.000101	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—JAK2—hematologic cancer	7.71e-05	0.000832	CbGpPWpGaD
Vigabatrin—Hypersensitivity—Prednisolone—hematologic cancer	7.71e-05	0.0001	CcSEcCtD
Vigabatrin—Hypoaesthesia—Doxorubicin—hematologic cancer	7.71e-05	0.0001	CcSEcCtD
Vigabatrin—Dyspepsia—Dexamethasone—hematologic cancer	7.68e-05	0.0001	CcSEcCtD
Vigabatrin—Dyspepsia—Betamethasone—hematologic cancer	7.68e-05	0.0001	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—MAP2K1—hematologic cancer	7.68e-05	0.000829	CbGpPWpGaD
Vigabatrin—Urticaria—Triamcinolone—hematologic cancer	7.64e-05	9.94e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—GRB2—hematologic cancer	7.64e-05	0.000824	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CD—hematologic cancer	7.63e-05	0.000823	CbGpPWpGaD
Vigabatrin—Oedema peripheral—Doxorubicin—hematologic cancer	7.63e-05	9.92e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PDGFA—hematologic cancer	7.62e-05	0.000822	CbGpPWpGaD
Vigabatrin—Asthenia—Etoposide—hematologic cancer	7.61e-05	9.9e-05	CcSEcCtD
Vigabatrin—Connective tissue disorder—Doxorubicin—hematologic cancer	7.61e-05	9.9e-05	CcSEcCtD
Vigabatrin—Body temperature increased—Triamcinolone—hematologic cancer	7.61e-05	9.89e-05	CcSEcCtD
Vigabatrin—Oedema—Prednisone—hematologic cancer	7.6e-05	9.89e-05	CcSEcCtD
Vigabatrin—Decreased appetite—Dexamethasone—hematologic cancer	7.59e-05	9.87e-05	CcSEcCtD
Vigabatrin—Decreased appetite—Betamethasone—hematologic cancer	7.59e-05	9.87e-05	CcSEcCtD
Vigabatrin—Nausea—Mitoxantrone—hematologic cancer	7.58e-05	9.85e-05	CcSEcCtD
Vigabatrin—Nausea—Irinotecan—hematologic cancer	7.58e-05	9.85e-05	CcSEcCtD
Vigabatrin—Infection—Prednisone—hematologic cancer	7.55e-05	9.83e-05	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Dexamethasone—hematologic cancer	7.54e-05	9.8e-05	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Betamethasone—hematologic cancer	7.54e-05	9.8e-05	CcSEcCtD
Vigabatrin—Back pain—Methotrexate—hematologic cancer	7.53e-05	9.8e-05	CcSEcCtD
Vigabatrin—Fatigue—Dexamethasone—hematologic cancer	7.53e-05	9.79e-05	CcSEcCtD
Vigabatrin—Fatigue—Betamethasone—hematologic cancer	7.53e-05	9.79e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—KITLG—hematologic cancer	7.51e-05	0.000811	CbGpPWpGaD
Vigabatrin—Pruritus—Etoposide—hematologic cancer	7.51e-05	9.76e-05	CcSEcCtD
Vigabatrin—Pain—Betamethasone—hematologic cancer	7.47e-05	9.71e-05	CcSEcCtD
Vigabatrin—Pain—Dexamethasone—hematologic cancer	7.47e-05	9.71e-05	CcSEcCtD
Vigabatrin—Visual impairment—Doxorubicin—hematologic cancer	7.46e-05	9.71e-05	CcSEcCtD
Vigabatrin—Nervous system disorder—Prednisone—hematologic cancer	7.46e-05	9.7e-05	CcSEcCtD
Vigabatrin—Skin disorder—Prednisone—hematologic cancer	7.38e-05	9.61e-05	CcSEcCtD
Vigabatrin—Nausea—Gemcitabine—hematologic cancer	7.38e-05	9.6e-05	CcSEcCtD
Vigabatrin—Vomiting—Cisplatin—hematologic cancer	7.36e-05	9.58e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—STAT5A—hematologic cancer	7.34e-05	0.000792	CbGpPWpGaD
Vigabatrin—Vision blurred—Methotrexate—hematologic cancer	7.34e-05	9.54e-05	CcSEcCtD
Vigabatrin—Mental disorder—Epirubicin—hematologic cancer	7.33e-05	9.54e-05	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CB—hematologic cancer	7.32e-05	0.00079	CbGpPWpGaD
Vigabatrin—Erythema multiforme—Doxorubicin—hematologic cancer	7.32e-05	9.52e-05	CcSEcCtD
Vigabatrin—Rash—Cisplatin—hematologic cancer	7.3e-05	9.5e-05	CcSEcCtD
Vigabatrin—Dermatitis—Cisplatin—hematologic cancer	7.29e-05	9.49e-05	CcSEcCtD
Vigabatrin—Malnutrition—Epirubicin—hematologic cancer	7.29e-05	9.48e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CDKN2B—hematologic cancer	7.28e-05	0.000785	CbGpPWpGaD
Vigabatrin—Diarrhoea—Etoposide—hematologic cancer	7.26e-05	9.44e-05	CcSEcCtD
Vigabatrin—Eye disorder—Doxorubicin—hematologic cancer	7.24e-05	9.41e-05	CcSEcCtD
Vigabatrin—Ill-defined disorder—Methotrexate—hematologic cancer	7.22e-05	9.4e-05	CcSEcCtD
Vigabatrin—Tinnitus—Doxorubicin—hematologic cancer	7.22e-05	9.39e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3R1—hematologic cancer	7.21e-05	0.000777	CbGpPWpGaD
Vigabatrin—Anaemia—Methotrexate—hematologic cancer	7.2e-05	9.36e-05	CcSEcCtD
Vigabatrin—Feeling abnormal—Dexamethasone—hematologic cancer	7.19e-05	9.36e-05	CcSEcCtD
Vigabatrin—Feeling abnormal—Betamethasone—hematologic cancer	7.19e-05	9.36e-05	CcSEcCtD
Vigabatrin—Tension—Epirubicin—hematologic cancer	7.15e-05	9.3e-05	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Betamethasone—hematologic cancer	7.14e-05	9.29e-05	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Dexamethasone—hematologic cancer	7.14e-05	9.29e-05	CcSEcCtD
Vigabatrin—Hypersensitivity—Triamcinolone—hematologic cancer	7.09e-05	9.22e-05	CcSEcCtD
Vigabatrin—Nervousness—Epirubicin—hematologic cancer	7.08e-05	9.21e-05	CcSEcCtD
Vigabatrin—Back pain—Epirubicin—hematologic cancer	7.05e-05	9.17e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CD86—hematologic cancer	7.04e-05	0.00076	CbGpPWpGaD
Vigabatrin—Malaise—Methotrexate—hematologic cancer	7.02e-05	9.13e-05	CcSEcCtD
Vigabatrin—Dizziness—Etoposide—hematologic cancer	7.01e-05	9.12e-05	CcSEcCtD
Vigabatrin—Muscle spasms—Epirubicin—hematologic cancer	7e-05	9.11e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—JAK2—hematologic cancer	7e-05	0.000755	CbGpPWpGaD
Vigabatrin—Vertigo—Methotrexate—hematologic cancer	6.99e-05	9.1e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—HES1—hematologic cancer	6.95e-05	0.000749	CbGpPWpGaD
Vigabatrin—Urticaria—Betamethasone—hematologic cancer	6.94e-05	9.02e-05	CcSEcCtD
Vigabatrin—Urticaria—Dexamethasone—hematologic cancer	6.94e-05	9.02e-05	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.93e-05	9.01e-05	CcSEcCtD
Vigabatrin—Dizziness—Prednisolone—hematologic cancer	6.92e-05	9e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—NCOR1—hematologic cancer	6.91e-05	0.000745	CbGpPWpGaD
Vigabatrin—Asthenia—Triamcinolone—hematologic cancer	6.9e-05	8.98e-05	CcSEcCtD
Vigabatrin—Body temperature increased—Betamethasone—hematologic cancer	6.9e-05	8.98e-05	CcSEcCtD
Vigabatrin—Abdominal pain—Betamethasone—hematologic cancer	6.9e-05	8.98e-05	CcSEcCtD
Vigabatrin—Abdominal pain—Dexamethasone—hematologic cancer	6.9e-05	8.98e-05	CcSEcCtD
Vigabatrin—Body temperature increased—Dexamethasone—hematologic cancer	6.9e-05	8.98e-05	CcSEcCtD
Vigabatrin—Nausea—Cisplatin—hematologic cancer	6.88e-05	8.95e-05	CcSEcCtD
Vigabatrin—Insomnia—Prednisone—hematologic cancer	6.88e-05	8.95e-05	CcSEcCtD
Vigabatrin—Vision blurred—Epirubicin—hematologic cancer	6.87e-05	8.93e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—FGF1—hematologic cancer	6.83e-05	0.000737	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CSF2—hematologic cancer	6.83e-05	0.000737	CbGpPWpGaD
Vigabatrin—Paraesthesia—Prednisone—hematologic cancer	6.83e-05	8.88e-05	CcSEcCtD
Vigabatrin—Pruritus—Triamcinolone—hematologic cancer	6.81e-05	8.85e-05	CcSEcCtD
Vigabatrin—Cough—Methotrexate—hematologic cancer	6.79e-05	8.84e-05	CcSEcCtD
Vigabatrin—Mental disorder—Doxorubicin—hematologic cancer	6.78e-05	8.83e-05	CcSEcCtD
Vigabatrin—Ill-defined disorder—Epirubicin—hematologic cancer	6.76e-05	8.79e-05	CcSEcCtD
Vigabatrin—Convulsion—Methotrexate—hematologic cancer	6.75e-05	8.77e-05	CcSEcCtD
Vigabatrin—Vomiting—Etoposide—hematologic cancer	6.74e-05	8.77e-05	CcSEcCtD
Vigabatrin—Malnutrition—Doxorubicin—hematologic cancer	6.74e-05	8.77e-05	CcSEcCtD
Vigabatrin—Anaemia—Epirubicin—hematologic cancer	6.73e-05	8.76e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—FOXO1—hematologic cancer	6.73e-05	0.000726	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—IL2—hematologic cancer	6.73e-05	0.000726	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PDGFRB—hematologic cancer	6.72e-05	0.000725	CbGpPWpGaD
Vigabatrin—Agitation—Epirubicin—hematologic cancer	6.7e-05	8.71e-05	CcSEcCtD
Vigabatrin—Dyspepsia—Prednisone—hematologic cancer	6.69e-05	8.71e-05	CcSEcCtD
Vigabatrin—Rash—Etoposide—hematologic cancer	6.69e-05	8.7e-05	CcSEcCtD
Vigabatrin—Dermatitis—Etoposide—hematologic cancer	6.68e-05	8.69e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CB—hematologic cancer	6.65e-05	0.000717	CbGpPWpGaD
Vigabatrin—Headache—Etoposide—hematologic cancer	6.65e-05	8.64e-05	CcSEcCtD
Vigabatrin—Arthralgia—Methotrexate—hematologic cancer	6.63e-05	8.62e-05	CcSEcCtD
Vigabatrin—Chest pain—Methotrexate—hematologic cancer	6.63e-05	8.62e-05	CcSEcCtD
Vigabatrin—Myalgia—Methotrexate—hematologic cancer	6.63e-05	8.62e-05	CcSEcCtD
Vigabatrin—Tension—Doxorubicin—hematologic cancer	6.62e-05	8.61e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PDGFRA—hematologic cancer	6.61e-05	0.000713	CbGpPWpGaD
Vigabatrin—Decreased appetite—Prednisone—hematologic cancer	6.61e-05	8.6e-05	CcSEcCtD
Vigabatrin—Rash—Prednisolone—hematologic cancer	6.6e-05	8.58e-05	CcSEcCtD
Vigabatrin—Dermatitis—Prednisolone—hematologic cancer	6.59e-05	8.57e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—JAK1—hematologic cancer	6.59e-05	0.000711	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PRKCG—hematologic cancer	6.59e-05	0.000711	CbGpPWpGaD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.58e-05	8.56e-05	CcSEcCtD
Vigabatrin—Malaise—Epirubicin—hematologic cancer	6.57e-05	8.55e-05	CcSEcCtD
Vigabatrin—Fatigue—Prednisone—hematologic cancer	6.55e-05	8.53e-05	CcSEcCtD
Vigabatrin—Headache—Prednisolone—hematologic cancer	6.55e-05	8.53e-05	CcSEcCtD
Vigabatrin—Discomfort—Methotrexate—hematologic cancer	6.55e-05	8.52e-05	CcSEcCtD
Vigabatrin—Nervousness—Doxorubicin—hematologic cancer	6.55e-05	8.52e-05	CcSEcCtD
Vigabatrin—Vertigo—Epirubicin—hematologic cancer	6.55e-05	8.52e-05	CcSEcCtD
Vigabatrin—Back pain—Doxorubicin—hematologic cancer	6.52e-05	8.48e-05	CcSEcCtD
Vigabatrin—Constipation—Prednisone—hematologic cancer	6.5e-05	8.46e-05	CcSEcCtD
Vigabatrin—Muscle spasms—Doxorubicin—hematologic cancer	6.48e-05	8.43e-05	CcSEcCtD
Vigabatrin—Confusional state—Methotrexate—hematologic cancer	6.41e-05	8.33e-05	CcSEcCtD
Vigabatrin—Dizziness—Triamcinolone—hematologic cancer	6.36e-05	8.28e-05	CcSEcCtD
Vigabatrin—Cough—Epirubicin—hematologic cancer	6.36e-05	8.27e-05	CcSEcCtD
Vigabatrin—Vision blurred—Doxorubicin—hematologic cancer	6.35e-05	8.26e-05	CcSEcCtD
Vigabatrin—Convulsion—Epirubicin—hematologic cancer	6.31e-05	8.21e-05	CcSEcCtD
Vigabatrin—Infection—Methotrexate—hematologic cancer	6.31e-05	8.21e-05	CcSEcCtD
Vigabatrin—Nausea—Etoposide—hematologic cancer	6.3e-05	8.2e-05	CcSEcCtD
Vigabatrin—Feeling abnormal—Prednisone—hematologic cancer	6.27e-05	8.15e-05	CcSEcCtD
Vigabatrin—Asthenia—Dexamethasone—hematologic cancer	6.26e-05	8.15e-05	CcSEcCtD
Vigabatrin—Asthenia—Betamethasone—hematologic cancer	6.26e-05	8.15e-05	CcSEcCtD
Vigabatrin—Ill-defined disorder—Doxorubicin—hematologic cancer	6.26e-05	8.14e-05	CcSEcCtD
Vigabatrin—Nervous system disorder—Methotrexate—hematologic cancer	6.23e-05	8.11e-05	CcSEcCtD
Vigabatrin—Anaemia—Doxorubicin—hematologic cancer	6.23e-05	8.11e-05	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Prednisone—hematologic cancer	6.22e-05	8.09e-05	CcSEcCtD
Vigabatrin—Nausea—Prednisolone—hematologic cancer	6.21e-05	8.08e-05	CcSEcCtD
Vigabatrin—Myalgia—Epirubicin—hematologic cancer	6.2e-05	8.07e-05	CcSEcCtD
Vigabatrin—Chest pain—Epirubicin—hematologic cancer	6.2e-05	8.07e-05	CcSEcCtD
Vigabatrin—Arthralgia—Epirubicin—hematologic cancer	6.2e-05	8.07e-05	CcSEcCtD
Vigabatrin—Agitation—Doxorubicin—hematologic cancer	6.2e-05	8.06e-05	CcSEcCtD
Vigabatrin—Anxiety—Epirubicin—hematologic cancer	6.18e-05	8.04e-05	CcSEcCtD
Vigabatrin—Pruritus—Dexamethasone—hematologic cancer	6.18e-05	8.03e-05	CcSEcCtD
Vigabatrin—Pruritus—Betamethasone—hematologic cancer	6.18e-05	8.03e-05	CcSEcCtD
Vigabatrin—Skin disorder—Methotrexate—hematologic cancer	6.17e-05	8.03e-05	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	6.16e-05	8.01e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—IL2RA—hematologic cancer	6.16e-05	0.000664	CbGpPWpGaD
Vigabatrin—Discomfort—Epirubicin—hematologic cancer	6.13e-05	7.97e-05	CcSEcCtD
Vigabatrin—Vomiting—Triamcinolone—hematologic cancer	6.12e-05	7.96e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—IL2—hematologic cancer	6.11e-05	0.000659	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TERT—hematologic cancer	6.09e-05	0.000657	CbGpPWpGaD
Vigabatrin—Malaise—Doxorubicin—hematologic cancer	6.08e-05	7.91e-05	CcSEcCtD
Vigabatrin—Rash—Triamcinolone—hematologic cancer	6.07e-05	7.89e-05	CcSEcCtD
Vigabatrin—Dermatitis—Triamcinolone—hematologic cancer	6.06e-05	7.88e-05	CcSEcCtD
Vigabatrin—Vertigo—Doxorubicin—hematologic cancer	6.06e-05	7.88e-05	CcSEcCtD
Vigabatrin—Urticaria—Prednisone—hematologic cancer	6.04e-05	7.86e-05	CcSEcCtD
Vigabatrin—Headache—Triamcinolone—hematologic cancer	6.03e-05	7.84e-05	CcSEcCtD
Vigabatrin—Abdominal pain—Prednisone—hematologic cancer	6.01e-05	7.82e-05	CcSEcCtD
Vigabatrin—Body temperature increased—Prednisone—hematologic cancer	6.01e-05	7.82e-05	CcSEcCtD
Vigabatrin—Confusional state—Epirubicin—hematologic cancer	6e-05	7.8e-05	CcSEcCtD
Vigabatrin—Diarrhoea—Betamethasone—hematologic cancer	5.97e-05	7.77e-05	CcSEcCtD
Vigabatrin—Diarrhoea—Dexamethasone—hematologic cancer	5.97e-05	7.77e-05	CcSEcCtD
Vigabatrin—Oedema—Epirubicin—hematologic cancer	5.95e-05	7.73e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PDGFB—hematologic cancer	5.94e-05	0.000641	CbGpPWpGaD
Vigabatrin—Infection—Epirubicin—hematologic cancer	5.91e-05	7.68e-05	CcSEcCtD
Vigabatrin—Cough—Doxorubicin—hematologic cancer	5.88e-05	7.65e-05	CcSEcCtD
Vigabatrin—Convulsion—Doxorubicin—hematologic cancer	5.84e-05	7.6e-05	CcSEcCtD
Vigabatrin—Nervous system disorder—Epirubicin—hematologic cancer	5.83e-05	7.59e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—TSC2—hematologic cancer	5.81e-05	0.000626	CbGpPWpGaD
Vigabatrin—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.79e-05	7.53e-05	CcSEcCtD
Vigabatrin—Skin disorder—Epirubicin—hematologic cancer	5.78e-05	7.51e-05	CcSEcCtD
Vigabatrin—Dizziness—Dexamethasone—hematologic cancer	5.77e-05	7.51e-05	CcSEcCtD
Vigabatrin—Dizziness—Betamethasone—hematologic cancer	5.77e-05	7.51e-05	CcSEcCtD
Vigabatrin—Insomnia—Methotrexate—hematologic cancer	5.75e-05	7.48e-05	CcSEcCtD
Vigabatrin—Chest pain—Doxorubicin—hematologic cancer	5.74e-05	7.47e-05	CcSEcCtD
Vigabatrin—Myalgia—Doxorubicin—hematologic cancer	5.74e-05	7.47e-05	CcSEcCtD
Vigabatrin—Arthralgia—Doxorubicin—hematologic cancer	5.74e-05	7.47e-05	CcSEcCtD
Vigabatrin—Anxiety—Doxorubicin—hematologic cancer	5.72e-05	7.44e-05	CcSEcCtD
Vigabatrin—Nausea—Triamcinolone—hematologic cancer	5.72e-05	7.43e-05	CcSEcCtD
Vigabatrin—Paraesthesia—Methotrexate—hematologic cancer	5.71e-05	7.42e-05	CcSEcCtD
Vigabatrin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.7e-05	7.41e-05	CcSEcCtD
Vigabatrin—Discomfort—Doxorubicin—hematologic cancer	5.67e-05	7.38e-05	CcSEcCtD
Vigabatrin—Somnolence—Methotrexate—hematologic cancer	5.65e-05	7.35e-05	CcSEcCtD
Vigabatrin—Hypersensitivity—Prednisone—hematologic cancer	5.6e-05	7.29e-05	CcSEcCtD
Vigabatrin—Dyspepsia—Methotrexate—hematologic cancer	5.59e-05	7.28e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—FGFR3—hematologic cancer	5.59e-05	0.000602	CbGpPWpGaD
Vigabatrin—Vomiting—Dexamethasone—hematologic cancer	5.55e-05	7.22e-05	CcSEcCtD
Vigabatrin—Vomiting—Betamethasone—hematologic cancer	5.55e-05	7.22e-05	CcSEcCtD
Vigabatrin—Confusional state—Doxorubicin—hematologic cancer	5.55e-05	7.22e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—MAPK14—hematologic cancer	5.53e-05	0.000596	CbGpPWpGaD
Vigabatrin—Decreased appetite—Methotrexate—hematologic cancer	5.52e-05	7.19e-05	CcSEcCtD
Vigabatrin—Rash—Betamethasone—hematologic cancer	5.5e-05	7.16e-05	CcSEcCtD
Vigabatrin—Rash—Dexamethasone—hematologic cancer	5.5e-05	7.16e-05	CcSEcCtD
Vigabatrin—Oedema—Doxorubicin—hematologic cancer	5.5e-05	7.16e-05	CcSEcCtD
Vigabatrin—Dermatitis—Betamethasone—hematologic cancer	5.5e-05	7.15e-05	CcSEcCtD
Vigabatrin—Dermatitis—Dexamethasone—hematologic cancer	5.5e-05	7.15e-05	CcSEcCtD
Vigabatrin—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.49e-05	7.14e-05	CcSEcCtD
Vigabatrin—Fatigue—Methotrexate—hematologic cancer	5.48e-05	7.13e-05	CcSEcCtD
Vigabatrin—Headache—Dexamethasone—hematologic cancer	5.47e-05	7.11e-05	CcSEcCtD
Vigabatrin—Headache—Betamethasone—hematologic cancer	5.47e-05	7.11e-05	CcSEcCtD
Vigabatrin—Infection—Doxorubicin—hematologic cancer	5.47e-05	7.11e-05	CcSEcCtD
Vigabatrin—Asthenia—Prednisone—hematologic cancer	5.45e-05	7.1e-05	CcSEcCtD
Vigabatrin—Pain—Methotrexate—hematologic cancer	5.43e-05	7.07e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—ESR1—hematologic cancer	5.42e-05	0.000585	CbGpPWpGaD
Vigabatrin—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.42e-05	7.05e-05	CcSEcCtD
Vigabatrin—Nervous system disorder—Doxorubicin—hematologic cancer	5.4e-05	7.02e-05	CcSEcCtD
Vigabatrin—Pruritus—Prednisone—hematologic cancer	5.38e-05	7e-05	CcSEcCtD
Vigabatrin—Insomnia—Epirubicin—hematologic cancer	5.38e-05	7e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—FN1—hematologic cancer	5.36e-05	0.000578	CbGpPWpGaD
Vigabatrin—Skin disorder—Doxorubicin—hematologic cancer	5.34e-05	6.95e-05	CcSEcCtD
Vigabatrin—Paraesthesia—Epirubicin—hematologic cancer	5.34e-05	6.95e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—NFKBIA—hematologic cancer	5.29e-05	0.000571	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—BAD—hematologic cancer	5.29e-05	0.000571	CbGpPWpGaD
Vigabatrin—Somnolence—Epirubicin—hematologic cancer	5.29e-05	6.88e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—NOTCH1—hematologic cancer	5.24e-05	0.000566	CbGpPWpGaD
Vigabatrin—Feeling abnormal—Methotrexate—hematologic cancer	5.24e-05	6.81e-05	CcSEcCtD
Vigabatrin—Dyspepsia—Epirubicin—hematologic cancer	5.23e-05	6.81e-05	CcSEcCtD
Vigabatrin—Diarrhoea—Prednisone—hematologic cancer	5.2e-05	6.77e-05	CcSEcCtD
Vigabatrin—Gastrointestinal pain—Methotrexate—hematologic cancer	5.2e-05	6.76e-05	CcSEcCtD
Vigabatrin—Nausea—Dexamethasone—hematologic cancer	5.19e-05	6.75e-05	CcSEcCtD
Vigabatrin—Nausea—Betamethasone—hematologic cancer	5.19e-05	6.75e-05	CcSEcCtD
Vigabatrin—Decreased appetite—Epirubicin—hematologic cancer	5.17e-05	6.72e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CD80—hematologic cancer	5.14e-05	0.000554	CbGpPWpGaD
Vigabatrin—Gastrointestinal disorder—Epirubicin—hematologic cancer	5.13e-05	6.68e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—KIT—hematologic cancer	5.13e-05	0.000553	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CG—hematologic cancer	5.13e-05	0.000553	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—NRAS—hematologic cancer	5.13e-05	0.000553	CbGpPWpGaD
Vigabatrin—Fatigue—Epirubicin—hematologic cancer	5.13e-05	6.67e-05	CcSEcCtD
Vigabatrin—Constipation—Epirubicin—hematologic cancer	5.08e-05	6.61e-05	CcSEcCtD
Vigabatrin—Pain—Epirubicin—hematologic cancer	5.08e-05	6.61e-05	CcSEcCtD
Vigabatrin—Urticaria—Methotrexate—hematologic cancer	5.05e-05	6.57e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PTPN11—hematologic cancer	5.04e-05	0.000543	CbGpPWpGaD
Vigabatrin—Dizziness—Prednisone—hematologic cancer	5.03e-05	6.54e-05	CcSEcCtD
Vigabatrin—Body temperature increased—Methotrexate—hematologic cancer	5.02e-05	6.53e-05	CcSEcCtD
Vigabatrin—Abdominal pain—Methotrexate—hematologic cancer	5.02e-05	6.53e-05	CcSEcCtD
Vigabatrin—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	5.01e-05	6.52e-05	CcSEcCtD
Vigabatrin—Insomnia—Doxorubicin—hematologic cancer	4.98e-05	6.47e-05	CcSEcCtD
Vigabatrin—Paraesthesia—Doxorubicin—hematologic cancer	4.94e-05	6.43e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—MAPK3—hematologic cancer	4.91e-05	0.00053	CbGpPWpGaD
Vigabatrin—Feeling abnormal—Epirubicin—hematologic cancer	4.9e-05	6.37e-05	CcSEcCtD
Vigabatrin—Somnolence—Doxorubicin—hematologic cancer	4.89e-05	6.36e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CREB1—hematologic cancer	4.88e-05	0.000527	CbGpPWpGaD
Vigabatrin—Gastrointestinal pain—Epirubicin—hematologic cancer	4.86e-05	6.33e-05	CcSEcCtD
Vigabatrin—Dyspepsia—Doxorubicin—hematologic cancer	4.84e-05	6.3e-05	CcSEcCtD
Vigabatrin—Vomiting—Prednisone—hematologic cancer	4.83e-05	6.29e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—BRAF—hematologic cancer	4.82e-05	0.00052	CbGpPWpGaD
Vigabatrin—Rash—Prednisone—hematologic cancer	4.79e-05	6.24e-05	CcSEcCtD
Vigabatrin—Dermatitis—Prednisone—hematologic cancer	4.79e-05	6.23e-05	CcSEcCtD
Vigabatrin—Decreased appetite—Doxorubicin—hematologic cancer	4.78e-05	6.22e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CCL2—hematologic cancer	4.78e-05	0.000515	CbGpPWpGaD
Vigabatrin—Headache—Prednisone—hematologic cancer	4.76e-05	6.2e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—IL6R—hematologic cancer	4.76e-05	0.000514	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—CREBBP—hematologic cancer	4.75e-05	0.000513	CbGpPWpGaD
Vigabatrin—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.75e-05	6.18e-05	CcSEcCtD
Vigabatrin—Fatigue—Doxorubicin—hematologic cancer	4.74e-05	6.17e-05	CcSEcCtD
Vigabatrin—Urticaria—Epirubicin—hematologic cancer	4.72e-05	6.14e-05	CcSEcCtD
Vigabatrin—Constipation—Doxorubicin—hematologic cancer	4.7e-05	6.12e-05	CcSEcCtD
Vigabatrin—Pain—Doxorubicin—hematologic cancer	4.7e-05	6.12e-05	CcSEcCtD
Vigabatrin—Abdominal pain—Epirubicin—hematologic cancer	4.7e-05	6.11e-05	CcSEcCtD
Vigabatrin—Body temperature increased—Epirubicin—hematologic cancer	4.7e-05	6.11e-05	CcSEcCtD
Vigabatrin—Hypersensitivity—Methotrexate—hematologic cancer	4.68e-05	6.09e-05	CcSEcCtD
Vigabatrin—Asthenia—Methotrexate—hematologic cancer	4.56e-05	5.93e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—MAP2K1—hematologic cancer	4.54e-05	0.000489	CbGpPWpGaD
Vigabatrin—Feeling abnormal—Doxorubicin—hematologic cancer	4.53e-05	5.9e-05	CcSEcCtD
Vigabatrin—Nausea—Prednisone—hematologic cancer	4.52e-05	5.87e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CD—hematologic cancer	4.51e-05	0.000486	CbGpPWpGaD
Vigabatrin—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.5e-05	5.85e-05	CcSEcCtD
Vigabatrin—Pruritus—Methotrexate—hematologic cancer	4.5e-05	5.85e-05	CcSEcCtD
Vigabatrin—GABBR1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.47e-05	0.000482	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—KRAS—hematologic cancer	4.41e-05	0.000476	CbGpPWpGaD
Vigabatrin—Hypersensitivity—Epirubicin—hematologic cancer	4.38e-05	5.7e-05	CcSEcCtD
Vigabatrin—Urticaria—Doxorubicin—hematologic cancer	4.37e-05	5.69e-05	CcSEcCtD
Vigabatrin—Abdominal pain—Doxorubicin—hematologic cancer	4.35e-05	5.66e-05	CcSEcCtD
Vigabatrin—Body temperature increased—Doxorubicin—hematologic cancer	4.35e-05	5.66e-05	CcSEcCtD
Vigabatrin—Diarrhoea—Methotrexate—hematologic cancer	4.35e-05	5.66e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—FGF2—hematologic cancer	4.32e-05	0.000466	CbGpPWpGaD
Vigabatrin—Asthenia—Epirubicin—hematologic cancer	4.27e-05	5.55e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PIK3R1—hematologic cancer	4.26e-05	0.000459	CbGpPWpGaD
Vigabatrin—Pruritus—Epirubicin—hematologic cancer	4.21e-05	5.47e-05	CcSEcCtD
Vigabatrin—Dizziness—Methotrexate—hematologic cancer	4.2e-05	5.47e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—JAK2—hematologic cancer	4.14e-05	0.000446	CbGpPWpGaD
Vigabatrin—Diarrhoea—Epirubicin—hematologic cancer	4.07e-05	5.29e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—PIK3CA—hematologic cancer	4.05e-05	0.000437	CbGpPWpGaD
Vigabatrin—Hypersensitivity—Doxorubicin—hematologic cancer	4.05e-05	5.27e-05	CcSEcCtD
Vigabatrin—Vomiting—Methotrexate—hematologic cancer	4.04e-05	5.26e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—MDM2—hematologic cancer	4.04e-05	0.000436	CbGpPWpGaD
Vigabatrin—Rash—Methotrexate—hematologic cancer	4.01e-05	5.21e-05	CcSEcCtD
Vigabatrin—Dermatitis—Methotrexate—hematologic cancer	4e-05	5.21e-05	CcSEcCtD
Vigabatrin—Headache—Methotrexate—hematologic cancer	3.98e-05	5.18e-05	CcSEcCtD
Vigabatrin—Asthenia—Doxorubicin—hematologic cancer	3.95e-05	5.13e-05	CcSEcCtD
Vigabatrin—Dizziness—Epirubicin—hematologic cancer	3.93e-05	5.11e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CB—hematologic cancer	3.93e-05	0.000424	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MTOR—hematologic cancer	3.93e-05	0.000424	CbGpPWpGaD
Vigabatrin—Pruritus—Doxorubicin—hematologic cancer	3.89e-05	5.06e-05	CcSEcCtD
Vigabatrin—Vomiting—Epirubicin—hematologic cancer	3.78e-05	4.92e-05	CcSEcCtD
Vigabatrin—Nausea—Methotrexate—hematologic cancer	3.77e-05	4.91e-05	CcSEcCtD
Vigabatrin—Diarrhoea—Doxorubicin—hematologic cancer	3.76e-05	4.9e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling by GPCR—HRAS—hematologic cancer	3.75e-05	0.000405	CbGpPWpGaD
Vigabatrin—Rash—Epirubicin—hematologic cancer	3.75e-05	4.88e-05	CcSEcCtD
Vigabatrin—Dermatitis—Epirubicin—hematologic cancer	3.75e-05	4.87e-05	CcSEcCtD
Vigabatrin—Headache—Epirubicin—hematologic cancer	3.73e-05	4.85e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CDKN1B—hematologic cancer	3.69e-05	0.000398	CbGpPWpGaD
Vigabatrin—GABBR1—GPCR downstream signaling—AKT1—hematologic cancer	3.65e-05	0.000393	CbGpPWpGaD
Vigabatrin—Dizziness—Doxorubicin—hematologic cancer	3.64e-05	4.73e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CASP3—hematologic cancer	3.61e-05	0.00039	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IL2—hematologic cancer	3.61e-05	0.000389	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—IL6—hematologic cancer	3.59e-05	0.000387	CbGpPWpGaD
Vigabatrin—Nausea—Epirubicin—hematologic cancer	3.53e-05	4.59e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CCND1—hematologic cancer	3.52e-05	0.000379	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—JUN—hematologic cancer	3.51e-05	0.000379	CbGpPWpGaD
Vigabatrin—Vomiting—Doxorubicin—hematologic cancer	3.5e-05	4.55e-05	CcSEcCtD
Vigabatrin—Rash—Doxorubicin—hematologic cancer	3.47e-05	4.51e-05	CcSEcCtD
Vigabatrin—Dermatitis—Doxorubicin—hematologic cancer	3.47e-05	4.51e-05	CcSEcCtD
Vigabatrin—Headache—Doxorubicin—hematologic cancer	3.45e-05	4.48e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—CDKN1A—hematologic cancer	3.4e-05	0.000367	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PTEN—hematologic cancer	3.4e-05	0.000366	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MAPK8—hematologic cancer	3.32e-05	0.000358	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling by GPCR—AKT1—hematologic cancer	3.31e-05	0.000357	CbGpPWpGaD
Vigabatrin—Nausea—Doxorubicin—hematologic cancer	3.27e-05	4.25e-05	CcSEcCtD
Vigabatrin—GABBR1—Signaling Pathways—EP300—hematologic cancer	3.24e-05	0.000349	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—SRC—hematologic cancer	3.15e-05	0.00034	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—VEGFA—hematologic cancer	3.07e-05	0.000331	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—STAT3—hematologic cancer	3.04e-05	0.000328	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—NRAS—hematologic cancer	3.03e-05	0.000327	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MAPK3—hematologic cancer	2.9e-05	0.000313	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—MYC—hematologic cancer	2.82e-05	0.000304	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TGFB1—hematologic cancer	2.81e-05	0.000304	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—KRAS—hematologic cancer	2.61e-05	0.000281	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—PIK3CA—hematologic cancer	2.4e-05	0.000258	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—TP53—hematologic cancer	2.32e-05	0.00025	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—HRAS—hematologic cancer	2.22e-05	0.000239	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—IL6—hematologic cancer	2.12e-05	0.000229	CbGpPWpGaD
Vigabatrin—GABBR1—Signaling Pathways—AKT1—hematologic cancer	1.96e-05	0.000211	CbGpPWpGaD
